Disease

Solid Tumors

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · PHASE 1/2 TRIAL

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

ClinicalTrials.gov

Early-phase trial (Phase 1/2) with no reported results; registry record describes planned study design and endpoints only, typical of first-in-human or dose-escalation work.

PreliminarySolid Tumors NCT05315700 ORIC-114

Reported

Planned enrollment350

Study phasePhase 1/2

Primary outcome measure (dose-fin…Recommended Phase 2 Dose (RP2D) at 12 months

AUG 13, 2026 · OBSERVATIONAL STUDY

Mobile Sensor Technologies to Assess General Symptomology of People With Cancer

ClinicalTrials.gov

This is a completed observational registry study with no reported results; it describes methods for collecting sensor data from cancer patients to assess symptoms, but outcomes have not yet been published or registered.

PreliminarySolid Tumors National Cancer Institute (NCI)NCT04465214

Reported

Sample size49

Follow-up duration4 months

Primary outcome measuresPRO-CTCAE, Neuro-QOL, Numeric Rating Scale…

JUL 14, 2026 · JOURNAL ARTICLE

xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.

Cancer Biology & Therapy

Exploratory retrospective analysis identifying genomic alteration patterns and associations, requiring prospective validation before clinical implementation.

PreliminarySolid Tumors Xinguang Han Zhongyu Lu

Reported

Sample size2,144

Tumor types analyzed18

PI4K/PIPK alteration frequency10.5%